Jasper Therapeutics Inc
Veridion Score
Composite trend over time
Why is JSPR moving today?
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for JSPR.
JSPR insider activity
Jasper Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $347K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-24 | 2025-09-22 | Shizuru Judith Anne | Insider | buy | $2.43 | 41,000 | 156,901 | $100K | SEC Form 4 |
| 2025-09-24 | 2025-09-22 | Lucas Svetlana | Insider | buy | $2.43 | 20,000 | 20,000 | $49K | SEC Form 4 |
| 2025-09-24 | 2025-09-22 | WIGGANS THOMAS G | Insider | buy | $2.43 | 41,000 | 41,000 | $100K | SEC Form 4 |
| 2025-09-24 | 2025-09-22 | MARTELL RON | Insider | buy | $2.43 | 41,000 | 74,118 | $100K | SEC Form 4 |
JSPR contract awards, year to date.
Public federal awards linked to this ticker.
JSPR lobbying filings, year to date.
Registered lobbying filings matched to Jasper Therapeutics Inc.